Logo

Merck & Daiichi Sankyo Report the P-II (IDeate-Lung01) Study Data of Ifinatamab Deruxtecan to Treat Extensive-Stage Small Cell Lung Cancer

Share this

Merck & Daiichi Sankyo Report the P-II (IDeate-Lung01) Study Data of Ifinatamab Deruxtecan to Treat Extensive-Stage Small Cell Lung Cancer

Shots:

  • The P-II (IDeate-Lung01) study is assessing ifinatamab deruxtecan in ES-SCLC patients previously treated with 1-3L of therapies, to receive 8mg/kg or 12mg/kg (part 1), & at least 2L of therapy, to receive the recommended 12mg/kg (part 2)
  • Results showed cORR: 54.8% with 23 PRs (12mg/kg) & 26.1% with 1 CR and 11 PRs (8mg/kg), mDoR: 4.2mos. & 7.9mos., DCR: 90.5% & 80.4%, mPFS: 5.5mos. & 4.2mos. and mOS: 11.8mos. & 9.4mos. The 12mg/kg dose is selected for the expansion phase
  • In patients with brain target lesions intracranial ORRs were 50.0% with 3 PRs (12mg/kg, n=10) & 66.7% with 2 PRs (8mg/kg, n=6), 2 CRs were found in each cohort. Stable disease was observed in 5 (12mg/kg) & 2 cases (8mg/kg)

Ref: Merck | Image: Merck & Daiichi Sankyo

Related News:- Merck and Daiichi Sankyo Report the Initiation of P-III (IDeate-Lung02) Study of Ifinatamab Deruxtecan to Treat Small Cell Lung Cancer

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Disha Nankani

Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions